Clinician referral to a 12-week program ups vigorous exercise levels and improves mental health.
Prolonged androgen deprivation treatment ups risk in older men with prostate cancer, especially those with comorbidities.
Obesity is associated with greater risk of PCa among African-American men compared to non-Hispanic white men.
Enzalutamide improves health-related quality of life (HRQoL) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
Increased risks of mortality restricted to aspirin use after the diagnosis of prostate cancer.
Increased likelihood of prostate cancer seen with fourth repeat biopsy, men.
The Prostate Health Index improves detection of clinically significant prostate cancer.
Median time to death was shortest in men with metastatic disease at diagnosis.
High LDL cholesterol and high blood glucose, however, did increase the risk of PSA relapse.
Research raises concern about the simultaneous use of chemotherapy and fish oil.
Physical side effects seen over first 12 months of androgen deprivation therapy (ADT) persisted or worsened over 3 years of follow-up.
Researchers conclude that intermediate-risk PCa be stratified into favorable or unfavorable risk subgroups.
In a small study of mCRPC patients, the median time on therapy increased by nearly 100 days and PSA declined in some subjects.
Imaging was associated with a lower risk of positive surgical margins in men with cT1 prostate tumors, but not in other subgroups.
Within 10 years of surgery, men younger than 60 years are more likely to die from prostate cancer than from other causes.
Only 6.7% of men reported erections that were as good after radical prostatectomy, as before—much lower than would be expected by IIEF-5 scores.
Even patients who quit smoking less than 10 years after radical prostatectomy are at increased risk.
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
Low serum testosterone levels within the first year of androgen-deprivation therapy (ADT) is associated with improved cause-specific survival.
The researchers found that 12% of the participants experienced treatment decisional regret.
Highest risk during first 6 months of ADT among men who had cardiovascular events before treatment.
Also, no significant associations found between vitamin D-related SNPs and fatal prostate cancer
In a study, not a single case of metastatic disease developed among 449 men who had a tumor grade of Gleason 6 or less at radical prostatectomy.
Doctors should ask women about the medical history of their first-degree male relatives, researchers say
African American patients are less likely than Caucasians to receive intensity-modulated radiation therapy for localized prostate cancer.
Meta-analysis shows that use of medication is associated with an 18% lower risk.
Low-dose-rate brachytherapy boost (LDR-PB) achieves better rates of biochemically disease-free outcomes in prostate cancer.
The average time to return of continence and potency following prostatectomy was significantly shorter in the allograft than no-allograft group.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)